Albiglutide + insulin glargine

Albiglutide + insulin glargine is a combination therapy used in the management of type 2 diabetes mellitus. Albiglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that augments glucose-dependent insulin secretion and slows gastric emptying. Insulin glargine is a long-acting basal insulin analog that helps regulate blood glucose by facilitating cellular uptake of glucose and suppressing hepatic glucose production. This combination aims to improve glycemic control in adults with type 2 diabetes who are inadequately controlled on oral antidiabetic agents or basal insulin alone. Albiglutide was developed by GSK (GlaxoSmithKline) and marketed under the brand names Tanzeum and Eperzan, while insulin glargine is marketed as Lantus by Sanofi[2][3][4][5]. Clinical studies have shown that this combination can provide significant reductions in HbA1c levels compared to other regimens[4][6].